Multiple sclerosis other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:


==Other Diagnostic Studies==
==Other Diagnostic Studies==
====Evoked potential studies====
====Visual evoked potential studies====
 
Delay in response after stimulation of [[retina]] with light is an indicator of a problem in visual tracts due to [[Axonal|axona]]<nowiki/>l [[demyelination]].
The brain of a person with MS often responds less actively to stimulation of the [[optic nerve]] and [[sensory neuron|sensory nerves]]. These brain responses can be examined using [[visual evoked potential]]s (VEPs) and [[Sensory evoked potentials|somatosensory evoked potentials]] (SEPs). Decreased activity on either test can reveal demyelination which may be otherwise asymptomatic.  Along with other data, these exams can help find the widespread nerve involvement required for a definite diagnosis of MS.<ref>Gronseth GS; Ashman EJ. ''Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology.'' Neurology 2000 May 9;54(9):1720–5. PMID 10802774</ref>


==== Antimyelin antibodies ====
==== Antimyelin antibodies ====

Revision as of 14:18, 1 March 2018

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis other diagnostic studies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis other diagnostic studies

CDC on Multiple sclerosis other diagnostic studies

Multiple sclerosis other diagnostic studies in the news

Blogs on Multiple sclerosis other diagnostic studies

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Other Diagnostic Studies

Visual evoked potential studies

Delay in response after stimulation of retina with light is an indicator of a problem in visual tracts due to axonal demyelination.

Antimyelin antibodies

myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) thought to be a predictor of disease progression but some studies denied any relationship between these auto antibodies and disease severity or progression.[1][2][3][4]

References

  1. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (July 2003). "Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event". N. Engl. J. Med. 349 (2): 139–45. doi:10.1056/NEJMoa022328. PMID 12853586.
  2. Gaertner S, de Graaf KL, Greve B, Weissert R (December 2004). "Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis". Neurology. 63 (12): 2381–3. PMID 15623705.
  3. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R (January 2007). "Lack of association between antimyelin antibodies and progression to multiple sclerosis". N. Engl. J. Med. 356 (4): 371–8. doi:10.1056/NEJMoa063602. PMID 17251533.
  4. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G (June 2004). "Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects". Neurology. 62 (11): 2092–4. PMID 15184621.

Template:WH Template:WS